ALLO-329 - (RESOLUTION)

October 29, 2026: Allogene Therapeutics (NASDAQ: ALLO) announced upcoming November events, including a first clinical update for ALLO-329 and its Q3 2026 results call. For ALLO-329, an investigational dual anti-CD19/anti-CD70 allogeneic CAR T for autoimmune disease, the company will host a webinar on November 9, 2026 presenting preliminary safety and efficacy data from the ongoing Phase 1 RESOLUTION study in adults with autoimmune diseases including lupus, myositis, and scleroderma. The same preliminary Phase 1 results will also be presented that day at ACR Convergence 2026 in the “Systemic Sclerosis & Related Disorders – Treatment Poster Session B,” in a poster titled “Preliminary Safety and Efficacy Results from a First-in-Human Phase 1 Clinical Study of ALLO-329,” presented by Vivek Nagaraja, MD, FACR, Mayo Clinic Arizona, from 10:30 a.m. to 12:30 p.m. ET.

Separately, Allogene said it will report Q3 2026 financial results and provide a business update on November 5, 2026, followed by a webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. No clinical data were disclosed in this release; the catalyst is the scheduled preliminary Phase 1 ALLO-329 data presentation and webinar on November 9, 2026.